Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 5.31
MDVN's Cash to Debt is ranked lower than
60% of the 895 Companies
in the Global Biotechnology industry.

( Industry Median: 27.79 vs. MDVN: 5.31 )
Ranked among companies with meaningful Cash to Debt only.
MDVN' s Cash to Debt Range Over the Past 10 Years
Min: 1.1  Med: 9999.00 Max: No Debt
Current: 5.31
Equity to Asset 0.66
MDVN's Equity to Asset is ranked lower than
52% of the 670 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. MDVN: 0.66 )
Ranked among companies with meaningful Equity to Asset only.
MDVN' s Equity to Asset Range Over the Past 10 Years
Min: -0.02  Med: 0.49 Max: 0.99
Current: 0.66
-0.02
0.99
Interest Coverage 12.08
MDVN's Interest Coverage is ranked lower than
88% of the 410 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. MDVN: 12.08 )
Ranked among companies with meaningful Interest Coverage only.
MDVN' s Interest Coverage Range Over the Past 10 Years
Min: 12.99  Med: 10000.00 Max: 9999.99
Current: 12.08
12.99
9999.99
F-Score: 5
Z-Score: 11.84
M-Score: -0.78
WACC vs ROIC
9.83%
151.04%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 40.07
MDVN's Operating margin (%) is ranked higher than
94% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -70.14 vs. MDVN: 40.07 )
Ranked among companies with meaningful Operating margin (%) only.
MDVN' s Operating margin (%) Range Over the Past 10 Years
Min: -510.27  Med: -52.35 Max: 39.67
Current: 40.07
-510.27
39.67
Net-margin (%) 31.71
MDVN's Net-margin (%) is ranked higher than
92% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -66.97 vs. MDVN: 31.71 )
Ranked among companies with meaningful Net-margin (%) only.
MDVN' s Net-margin (%) Range Over the Past 10 Years
Min: -496.58  Med: -54.45 Max: 38.91
Current: 31.71
-496.58
38.91
ROE (%) 56.24
MDVN's ROE (%) is ranked higher than
99% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: -31.22 vs. MDVN: 56.24 )
Ranked among companies with meaningful ROE (%) only.
MDVN' s ROE (%) Range Over the Past 10 Years
Min: -862.65  Med: -99.86 Max: 105.07
Current: 56.24
-862.65
105.07
ROA (%) 30.23
MDVN's ROA (%) is ranked higher than
98% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. MDVN: 30.23 )
Ranked among companies with meaningful ROA (%) only.
MDVN' s ROA (%) Range Over the Past 10 Years
Min: -80.48  Med: -19.78 Max: 42.39
Current: 30.23
-80.48
42.39
ROC (Joel Greenblatt) (%) 213.83
MDVN's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -378.42 vs. MDVN: 213.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MDVN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -201825  Med: -5280.40 Max: 299.98
Current: 213.83
-201825
299.98
Revenue Growth (3Y)(%) 113.40
MDVN's Revenue Growth (3Y)(%) is ranked higher than
97% of the 440 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. MDVN: 113.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MDVN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -50.00 Max: 113.4
Current: 113.4
0
113.4
» MDVN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

MDVN Guru Trades in Q1 2015

Louis Moore Bacon 15,000 sh (New)
Joel Greenblatt 150,526 sh (+377.59%)
Jim Simons 434,231 sh (+68.90%)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
Ken Fisher 2,400 sh (-5.21%)
» More
Q2 2015

MDVN Guru Trades in Q2 2015

Steven Cohen 98,700 sh (New)
Jim Simons 795,100 sh (+83.11%)
Joel Greenblatt 250,394 sh (+66.35%)
Ken Fisher 2,400 sh (unchged)
Louis Moore Bacon Sold Out
» More
Q3 2015

MDVN Guru Trades in Q3 2015

Paul Tudor Jones 12,934 sh (New)
Steven Cohen 1,641,334 sh (+1562.95%)
Ken Fisher 6,300 sh (+162.50%)
Joel Greenblatt Sold Out
Jim Simons 694,700 sh (-12.63%)
» More
Q4 2015

MDVN Guru Trades in Q4 2015

Ken Fisher 6,615 sh (+5.00%)
» More
» Details

Insider Trades

Latest Guru Trades with MDVN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Medivation Inc

Weekly Insider Sells: Medivation, JPMorgan Chase, Stryker, Sabre Top insiders make large sales of stock
According to GuruFocus Insider Data, the largest insider sells during the past week were: Medivation Inc. (NASDAQ:MDVN), JPMorgan Chase & Co. (NYSE:JPM), Stryker Corporation (NYSE:SYK) and Sabre Corp. (NASDAQ:SABR). Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 20.11
MDVN's P/E(ttm) is ranked higher than
70% of the 376 Companies
in the Global Biotechnology industry.

( Industry Median: 30.34 vs. MDVN: 20.11 )
Ranked among companies with meaningful P/E(ttm) only.
MDVN' s P/E(ttm) Range Over the Past 10 Years
Min: 20.11  Med: 38.54 Max: 330.65
Current: 20.11
20.11
330.65
Forward P/E 13.44
MDVN's Forward P/E is ranked higher than
62% of the 343 Companies
in the Global Biotechnology industry.

( Industry Median: 16.89 vs. MDVN: 13.44 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 20.21
MDVN's PE(NRI) is ranked higher than
70% of the 272 Companies
in the Global Biotechnology industry.

( Industry Median: 31.50 vs. MDVN: 20.21 )
Ranked among companies with meaningful PE(NRI) only.
MDVN' s PE(NRI) Range Over the Past 10 Years
Min: 20.21  Med: 38.64 Max: 325.93
Current: 20.21
20.21
325.93
P/B 7.09
MDVN's P/B is ranked lower than
92% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. MDVN: 7.09 )
Ranked among companies with meaningful P/B only.
MDVN' s P/B Range Over the Past 10 Years
Min: 4.5  Med: 35.01 Max: 1848
Current: 7.09
4.5
1848
P/S 5.97
MDVN's P/S is ranked higher than
65% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 9.13 vs. MDVN: 5.97 )
Ranked among companies with meaningful P/S only.
MDVN' s P/S Range Over the Past 10 Years
Min: 4.45  Med: 22.71 Max: 845
Current: 5.97
4.45
845
PFCF 20.38
MDVN's PFCF is ranked higher than
62% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 28.21 vs. MDVN: 20.38 )
Ranked among companies with meaningful PFCF only.
MDVN' s PFCF Range Over the Past 10 Years
Min: 3.06  Med: 36.58 Max: 253.5
Current: 20.38
3.06
253.5
POCF 19.16
MDVN's POCF is ranked higher than
62% of the 383 Companies
in the Global Biotechnology industry.

( Industry Median: 28.02 vs. MDVN: 19.16 )
Ranked among companies with meaningful POCF only.
MDVN' s POCF Range Over the Past 10 Years
Min: 3.01  Med: 34.44 Max: 198.39
Current: 19.16
3.01
198.39
EV-to-EBIT 13.39
MDVN's EV-to-EBIT is ranked higher than
63% of the 450 Companies
in the Global Biotechnology industry.

( Industry Median: 20.72 vs. MDVN: 13.39 )
Ranked among companies with meaningful EV-to-EBIT only.
MDVN' s EV-to-EBIT Range Over the Past 10 Years
Min: -650.3  Med: -24.55 Max: 157.5
Current: 13.39
-650.3
157.5
EV-to-EBITDA 13.14
MDVN's EV-to-EBITDA is ranked higher than
59% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 18.13 vs. MDVN: 13.14 )
Ranked among companies with meaningful EV-to-EBITDA only.
MDVN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1185.6  Med: -24.85 Max: 144.7
Current: 13.14
-1185.6
144.7
Current Ratio 3.70
MDVN's Current Ratio is ranked lower than
56% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. MDVN: 3.70 )
Ranked among companies with meaningful Current Ratio only.
MDVN' s Current Ratio Range Over the Past 10 Years
Min: 1.46  Med: 3.81 Max: 27.3
Current: 3.7
1.46
27.3
Quick Ratio 3.70
MDVN's Quick Ratio is ranked lower than
54% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.43 vs. MDVN: 3.70 )
Ranked among companies with meaningful Quick Ratio only.
MDVN' s Quick Ratio Range Over the Past 10 Years
Min: 1.46  Med: 3.81 Max: 27.3
Current: 3.7
1.46
27.3
Days Sales Outstanding 120.59
MDVN's Days Sales Outstanding is ranked lower than
79% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: 62.58 vs. MDVN: 120.59 )
Ranked among companies with meaningful Days Sales Outstanding only.
MDVN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 34.21  Med: 94.91 Max: 143.37
Current: 120.59
34.21
143.37

Valuation & Return

vs
industry
vs
history
Price/Net Cash 33.88
MDVN's Price/Net Cash is ranked lower than
80% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. MDVN: 33.88 )
Ranked among companies with meaningful Price/Net Cash only.
MDVN' s Price/Net Cash Range Over the Past 10 Years
Min: 3  Med: 18.06 Max: 191.58
Current: 33.88
3
191.58
Price/Net Current Asset Value 10.44
MDVN's Price/Net Current Asset Value is ranked lower than
62% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: 7.24 vs. MDVN: 10.44 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
MDVN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.88  Med: 31.38 Max: 364
Current: 10.44
2.88
364
Price/Tangible Book 8.50
MDVN's Price/Tangible Book is ranked lower than
65% of the 1054 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. MDVN: 8.50 )
Ranked among companies with meaningful Price/Tangible Book only.
MDVN' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.3  Med: 13.33 Max: 1153
Current: 8.5
0.3
1153
Price/Projected FCF 7.11
MDVN's Price/Projected FCF is ranked lower than
71% of the 284 Companies
in the Global Biotechnology industry.

( Industry Median: 3.23 vs. MDVN: 7.11 )
Ranked among companies with meaningful Price/Projected FCF only.
MDVN' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.92  Med: 10.31 Max: 360
Current: 7.11
1.92
360
Price/Median PS Value 0.27
MDVN's Price/Median PS Value is ranked higher than
91% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MDVN: 0.27 )
Ranked among companies with meaningful Price/Median PS Value only.
MDVN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.19  Med: 0.76 Max: 3.87
Current: 0.27
0.19
3.87
Price/Graham Number 2.60
MDVN's Price/Graham Number is ranked higher than
72% of the 300 Companies
in the Global Biotechnology industry.

( Industry Median: 3.20 vs. MDVN: 2.60 )
Ranked among companies with meaningful Price/Graham Number only.
MDVN' s Price/Graham Number Range Over the Past 10 Years
Min: 3.79  Med: 6.22 Max: 21.41
Current: 2.6
3.79
21.41
Earnings Yield (Greenblatt) (%) 7.52
MDVN's Earnings Yield (Greenblatt) (%) is ranked higher than
88% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. MDVN: 7.52 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MDVN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.6  Med: 3.00 Max: 7.52
Current: 7.52
0.6
7.52

More Statistics

Revenue(Mil) $840
EPS $ 1.44
Beta1.06
Short Percentage of Float2.86%
52-Week Range $28.47 - 70.79
Shares Outstanding(Mil)163.71

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 888 911 1,205 1,525
EPS($) 0.87 1.39 2.31 3.20
EPS without NRI($) 0.87 1.39 2.31 3.20

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:WMD.Germany,
Medivation Inc was formed in Delaware in October 1995. The Company is a biopharmaceutical company engaged in the rapid development of novel small molecule drugs to treat diseases for which there are limited treatment options. Together with its collaboration partner Astellas Pharma Inc., or Astellas, the Company is developing XTANDI enzalutamide capsules. Together with Astellas, it is also conducting multiple trials of enzalutamide in earlier prostate cancer disease states, including the Phase 3 PREVAIL trial in patients with mCRPC who have not received chemotherapy, or pre-chemotherapy mCRPC patients, and in patients with breast cancer. Based on the positive results of the AFFIRM trial, the Company has exercised its right under its collaboration agreement with Astellas to co-promote XTANDI in the U.S., should it receive marketing approval. Their subsidiaries are Medivation Prostate Therapeutics Inc or MPT, Medivation Neurology Inc or MNI, Medivation Technologies Inc, or MTI, Medivation Field Solutions, Inc., or MFSI, and Medivation Services, Inc., or MSI. MPT holds the intellectual property rights covering XTANDI. MNI holds the intellectual property rights covering dimebon, which was in development for Alzheimer's disease and Huntington disease under its former collaboration with Pfizer. MTI holds the intellectual property rights covering its early-stage technologies. MFSI provides commercialization services to the Company, and MSI provides research and development services. It has received "Fast Track" designation from the U.S. Food and Drug Administration for the post-docetaxel indication. The Company is conducting this program in collaboration with Astellas. The Company is subject to extensive regulation by the Federal Food, Drug, and Cosmetic Act, or the FDC Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products.
» More Articles for MDVN

Headlines

Articles On GuruFocus.com
Weekly Insider Sells: Medivation, JPMorgan Chase, Stryker, Sabre Jan 26 2016 
Brean Capital Weighs in on Medivation Following Update on TERRAIN Study Mar 26 2015 
Wedbush Weighs in on Medivation Following Phase II TERRAIN Study Results Feb 03 2015 
Weekly CEO Sells Highlight: QAD Inc, Orbitz Worldwide Inc, Constellation Brands Inc, and Medivation Jan 25 2015 
William Blair’s Top BioPharmaceutical Stock Picks for Q1 2015 Dec 23 2014 
A Few Reasons Why Investors Should Consider Dendreon for Their Portfolio Aug 15 2014 
Weekly CEO Sells Highlight: Vringo Inc, Medivation Inc, BioDelivery Sciences International Inc and H Feb 02 2014 
Andreas Halvorsen Buys 2 Million Shares of Medivation Aug 22 2012 
Weekly CFO Sells Highlight: SLCA, UNH, LVS, RATE, MDVN, YUM, TER Feb 14 2012 
Interview with CEO of Cellceutix Corporation: Leo Ehrlich Nov 15 2011 

More From Other Websites
Technical Recap on Biotechnology Equities -- Biogen, Medivation, Grifols, and Agios Pharma Feb 05 2016
MEDIVATION, INC. Files SEC form 8-K, Regulation FD Disclosure Jan 29 2016
Medivation to Present at Leerink Partners 5th Annual Global Healthcare Conference Jan 27 2016
Medivation to Present at Leerink Partners 5th Annual Global Healthcare Conference Jan 27 2016
Opposing Views on Medivation News and Xtandi Jan 27 2016
Medivation downgraded by Canaccord Genuity Jan 27 2016
Journal of Clinical Oncology Publishes Results From the STRIVE Trial of Enzalutamide Compared to... Jan 26 2016
Journal of Clinical Oncology Publishes Results from the STRIVE trial of enzalutamide Compared to... Jan 26 2016
What Johnson & Johnson's Earnings Mean for Biotech Stocks Jan 26 2016
Weekly Insider Sells: Medivation, JPMorgan Chase, Stryker, Sabre Jan 26 2016
MEDIVATION, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jan 25 2016
Medivation (MDVN) Stock Gets ‘Outperform’ Rating at Credit Suisse Jan 21 2016
Astellas Pharma Europe: Lancet Oncology Publishes Results from the Phase 2 TERRAIN Trial of... Jan 14 2016
Astellas Pharma Europe: Lancet Oncology Publishes Results from the Phase 2 TERRAIN Trial of... Jan 14 2016
Lancet Oncology Publishes Results From the Phase 2 TERRAIN Trial of Enzalutamide Compared to... Jan 13 2016
Lancet Oncology Publishes Results from the Phase 2 TERRAIN Trial of enzalutamide Compared to... Jan 13 2016
Investors Can’t Get Enough of These 4 Stocks Today Jan 12 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK